



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/21/03 Signature: Joanne Ryan
(Joanne Ryan)

Docket No.: COTH-P01-001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Afeyan et al.

Application No.: 10/650592

Confirmation No.: 7920

Filed: August 27, 2003

Art Unit: 1614

For: ADZYMES AND USES THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. COTH-P01-001.

Dated: November 21, 2003

Respectfully submitted,

By 

John D. Quisel

Registration No.: 47,874
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/650592
				Filing Date	August 27, 2003
				First Named Inventor	Noubar B. Afeyan
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	COTH-P01-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA	2002/0019039-A1	02-14-2002	Davis et al.		
AB	4,671,958	06-09-1987	Rodwell et al.		
AC	5,935,823	08-10-1999	Fowlkes et al.		
AD	6,287,561	09-11-2001	Crea, R.		
AE	6,383,775-B1	05-07-2002	Duff et al.		
AF	6,399,355-B1	06-04-2002	Kwong et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BA	-WO 00/64485-A2		11-02-2000	Genencor International, Inc. et al.	
BB	-WO 90/02338-A1		03-08-1990	The General Hospital Corporation	
BC	-WO 01/42432-A2		06-14-2001	Medical Research Council	
BD	-WO 98/16633-A1		04-23-1998	Novo Nordisk A/S	
BE	-WO 02/055108-A1		07-18-2002	Centre National de la Recherche Scientifique et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		Author	Title	Item Type	Date	
CA	Bayer, E.A. et al. Affinity Cleavage and Targeted Catalysis of Proteins Using the Avidin-Biotin System. <i>Biochemistry</i> 29, 11274-79 (1990).					
CB	Bond, R. et al. Silicon Biotechnology: New Opportunities for Carbohydrate Science. <i>Aust. J. Chem.</i> 56, 7-11 (2003)					
CC	Bradbury, R.J. Protein Based Assembly of Nanoscale Parts. (May 1, 2003) Retrieved from http://www.aeiveos.com/~bradbury/Papers/PBAoNP.html on 8/25/03					
CD	Hosseini, M.W. Molecular Tectonics: From Simple Molecules to Complex Molecular Networks. <i>Universite Louis Pasteur, Strasbourg, France</i>					
CE	Alvarez, S. Engineering Protein Molecules for the Ordered Structuring of Silica. <i>National Nanofabrication Users Network</i> , pp. 82-3.					
CF	Davis, B.G. et al. Controlled Site-Selective Glycosylation of Proteins by a Combined Site-Directed Mutagenesis and Chemical Modification Approach. <i>J. Org. Chem.</i> 63, 9614-15 (1998)					
CG	Davis, B.G. et al. Selective Protein Degradation by Ligand-Targeted Enzymes: Towards the Creation of Catalytic Antagonists. <i>ChemBioChem</i> 4, 531-40 (2003)					
CH	Freitas, Jr., R.A. Mechanoenzymes: A non-SPM-based approach to molecular					

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/650592
				Filing Date	August 27, 2003
				First Named Inventor	Noubar B. Afeyan
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	COTH-P01-001

		mechanooassembly (February 21, 2000) Retrieved from http://www.aeiveos.com/~bradbury/Authors/Engineering/Freitas-RA/MAnSPMBAtMM.html on 8/25/03	
	CI	Sumerel, et al. Biotechnology Provides a New Route to Semiconductors. 2003	
	CJ	MacLennan, Bruce. Molecular Combinatory Computing for Nanostructure Synthesis and Control. Department of Computer Science, University of Tennessee	
	CK	Quake, S.R. et al. From Micro- to Nanofabrication with Soft Materials. Science 290, 1536-40 (November 24, 2000)	
	CL	Stupp, S.I. Self Assembly of Nanostructures and Functional Materials. Dept. of Materials Science and Engineering, Dept. of Chemistry, Feinberg Medical School, Northwestern University	
	CM	Whaley, S.R. et al. Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly. Nature 405, 665-68 (June 8, 2000)	
	CN	Zhou, Huan-Xiang. Quantitative Account of the Enhanced Affinity of Two Linked scFvs Specific for Different Epitopes on the Same Antigen. J. Mol. Biol. 329, 1-8 (2003)	
	CO	Maoz, R. et al. Self-Assembly and Nanofabrication: Is a Happy Marriage Possible? Department of Materials and Interfaces, The Weizmann Institute of Science, Rehovot, Israel	
	CP	Lim et al. BCR/ABL inhibition by an escort/phosphatase fusion protein. PNAS 97(22): 12233-12238 (2000)	
	CQ	Runge et al. Mol Biol Med Hybrid molecules: insights into plasminogen activator function. 1991 Apr 8(2):245-55	
	CR	Frankel et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets 2(1), 19-36 (2002)	
	CS	Springer et al. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT). Anticancer-Drug-Des. 11(8), 625-36 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--